Diffusion‐weighted <scp>MRI</scp> for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening

Sutherland, Tom; Watts, Jane; Galvin, Angela; Temple, Faye; Vuong, Jason; Little, Andrew F.

doi:10.1111/1754-9485.12513

Cited by 35 publications

(51 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an effort to maximize the potential value of cross-sectional MRI while minimizing contrast exposure, scanning time, and cost, abbreviated MRI examination protocols are being developed and tested in a number of centers [27, 28, 30, 52]. Ongoing studies may clarify the most appropriate niche for cost effective use of these modalities, perhaps particularly in those settings where US performs the least reliably, such as in individuals with truncal obesity.…”

Section: Computed Tomography and Magnetic Resonance Imagingmentioning

confidence: 99%

“…In addition, recent advances in next generation sequencing and molecular analysis of tumors, blood, stool and other analytes are producing what potentially may prove to be very exciting breakthroughs in biomarker technology, particularly assays of differentially methylated DNA regions and microRNAs. In parallel, we are seeing advances in imaging technology, such as studies of limited MRI exams performed using hepatobiliary contrast agents, and the development of novel ultrasound-based technologies [27–30]. These newer modalities may provide substantial advances over current US screening at similar or reduced cost.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

Mohammed

Roberts

2017

Curr Hepatology Rep

View full text Add to dashboard Cite

a) Purpose of review To address the controversy around the use of biomarkers for hepatocellular carcinoma (HCC) surveillance in individuals with cirrhosis or chronic hepatitis B who are at risk for development of liver cancer. b) Recent findings Recent studies suggest that surveillance for hepatocellular carcinoma is beneficial, even after adjustment for lead time and other biases. Alpha fetoprotein (AFP) is complementary to ultrasound (US) in surveillance, particularly in obese patients and patients with infiltrative tumors. US and AFP are both associated with harms to patients from false positive over-diagnosis, with US appearing to cause greater harms. Including patient demographic characteristics and additional biomarkers into diagnostic models is beneficial. Recent studies emphasize the advantage of time trends in biomarkers over single cross-sectional measurements. c) Summary AFP and other biomarkers are complementary to US in surveillance for HCC, especially when applied in models including patient variables and incorporating time trends in biomarker levels. With advances in genetic and molecular analysis of tumors, we may be poised at the cusp of a revolution in HCC surveillance.

show abstract

Section: Computed Tomography and Magnetic Resonance Imagingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

Mohammed

Roberts

2017

Curr Hepatology Rep

View full text Add to dashboard Cite

show abstract

“…However, AFP-negative HCC cannot be diagnosed easily and depends largely on imaging results, which often leads to misdiagnosis[6]. Thus, many HCC patients cannot obtain timely diagnosis and treatment.…”

Section: Introductionmentioning

confidence: 99%

Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma

Wang

Liu

Zheng

et al. 2017

WJG

View full text Add to dashboard Cite

AIMTo determine the prevalence and diagnostic value of autoantibodies in α-fetoprotein (AFP)-negative hepatocellular carcinoma (HCC).METHODSFifty-six serum samples from AFP-negative HCC cases, 86 from AFP-positive HCC cases, 168 from chronic liver disease cases, and 59 from normal human controls were included in this study. Autoantibodies to nucleophosmin (NPM)1, 14-3-3zeta and mouse double minute 2 homolog (MDM2) proteins in AFP-negative HCC serum were evaluated by enzyme-linked immunosorbent assay. Partially positive sera were further evaluated by western blotting. Immunohistochemistry was used to detect the expression of three tumor-associated antigens (TAAs) in AFP-negative HCC and normal control tissues.RESULTSThe frequency of autoantibodies to the three TAAs in AFP-negative HCC sera was 21.4%, 19.6% and 19.6%, which was significantly higher than in the chronic liver disease cases and normal human controls (P < 0.01) as well as AFP-positive HCC cases. The sensitivity of the three autoantibodies for diagnosis of AFP-negative HCC ranged from 19.6% to 21.4%, and the specificity was approximately 95%. When the three autoantibodies were combined, the sensitivity reached 30.4% and the specificity reached 91.6%.CONCLUSIONAutoantibodies to NPM1, 14-3-3zeta and MDM2 may be useful biomarkers for immunodiagnosis of AFP-negative HCC.

show abstract

“…Conversely, Nasu et al, in a series of 125 resected HCCs (sizes range: 0.8–15 cm), found no correlation between histological grade and ADC (using b factors of 0 and 500 s/mm 2 ), although the DWI and Signal Intensity of the HCCs increased in higher grade [76]. Sutherland et al [77] compared ultrasound screening with DWI for detecting HCC. The sensitivity, specificity, positive predictive value and negative predictive values for US were 100, 90, 23 and 100%, respectively, while for MRI were 83, 98, 63 and 99%.…”

Section: Hypointense Signal On Hepatobiliary Phasementioning

confidence: 99%

“…The reasons for the low false-positive rate of DWI include: not depicting macro regenerative and low grade dysplastic nodules and not depicting focal fatty heterogeneity, also the ability to correctly classify benign nodules as cavernous haemangiomas which usually have elevated apparent diffusion coefficient (ADC) values. They concluded that more studies are needed to validate the DWI as a screening tool and therefore it should replace US as a cost-effective screening tool [77]. DWI could be used as a helpful diagnostic tool for HCC in patients with chronic liver disease, since DWI can accurately detect HCC in patients with chronic liver disease regardless of the lesion size (Fig.…”

Section: Hypointense Signal On Hepatobiliary Phasementioning

confidence: 99%

Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update

Granata

Fusco

Avallone

et al. 2017

Infect Agents Cancer

View full text Add to dashboard Cite

Liver Imaging Reporting and Data System (LI-RADS) is a system for interpreting and reporting of imaging features on multidetector computed tomography (MDCT) and magnetic resonance (MR) studies in patients at risk for hepatocellular carcinoma (HCC). American College of Radiology (ACR) sustained the spread of LI-RADS to homogenizing the interpreting and reporting data of HCC patients. Diagnosis of HCC is due to the presence of major imaging features. Major features are imaging data used to categorize LI-RADS-3, LI-RADS-4, and LI-RADS-5 and include arterial-phase hyperenhancement, tumor diameter, washout appearance, capsule appearance and threshold growth. Ancillary are features that can be used to modify the LI-RADS classification. Ancillary features supporting malignancy (diffusion restriction, moderate T2 hyperintensity, T1 hypointensity on hapatospecifc phase) can be used to upgrade category by one or more categories, but not beyond LI-RADS-4. Our purpose is reporting an overview and update of major and ancillary MR imaging features in assessment of HCC.

show abstract

Diffusion‐weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening

Abstract: In patients with chronic liver disease undergoing surveillance for hepatocellular carcinoma, DWI MRI screening shows similar sensitivity to screening ultrasound but with a significantly lower false-positive rate.

Cited by 35 publications

References 27 publications

Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma

Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update

Contact Info

Product

Resources

About